PTC Therapeutics, Inc. (PTCT) News



PTC Therapeutics, Inc. (PTCT)

Today's Latest Price: $68.49 USD

0.23 (-0.33%)

Updated Jan 15 4:00pm

Add PTCT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 483 in Biotech

See all "A" rated Strong Buy stocks

StocksNews Articles for PTCT

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest PTCT News From Around the Web

Below are the latest news stories about Ptc Therapeutics Inc that investors may wish to consider to help them evaluate PTCT as an investment opportunity.

PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the seventh annual STRIVE Awards program for Duchenne muscular dystrophy. The Awards provide a grant to patient advocacy organizations around the world who are committed to developing innovative and sustaining programs that help address the unmet needs of the rare disease community. This year, a new entry category dedicated to supporting programs that focus on the transition of those living with Duchenne from adolescence to adulthood has been introduced.

Yahoo | January 14, 2021

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate of 13,465 shares of its common stock and 4,665 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 10 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation.

Yahoo | January 13, 2021

PTC Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11th at 7:30 a.m. EST.

Yahoo | January 4, 2021

Ptc Therapeutics Inc (PTCT) CEO Stuart Walter Peltz Sold $1.2 million of Shares

CEO of Ptc Therapeutics Inc (30-Year Financial, Insider Trades) Stuart Walter Peltz (insider trades) sold 20,017 shares of PTCT on 12/07/2020 at an average price of $61.42 a share.

Yahoo Finance | December 9, 2020

PTC Therapeutics to Host Translarna™ Deep Dive Webinar

PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing Translarna on Tuesday, December 15 at 12:00 noon ET.

Yahoo | December 9, 2020

PTC Therapeutics Reviews Inducement Grants Below Nasdaq Itemizing Rule 5635(c)(4)

PTC Therapeutics Reviews Inducement Grants Below Nasdaq Itemizing Rule 5635(c)(4) -

Fintech Zoom | December 4, 2020

PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia

PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the registration-directed Phase 3 MOVE-FA study evaluating vatiquinone (PTC743) in children and young adults with Friedreich ataxia (FA). FA is a genetic, progressive, neurodegenerative movement disorder, typically diagnosed in childhood or adolescence.1 PTC estimates that there are 25,000 patients with FA worldwide and there are currently no approved disease modifying therapies for FA. In a previous Phase 2 trial, vatiquinone demonstrated a statistically significant effect on disease severity at 24 months relative to age and stage-matched natural history controls as assessed by the validated Friedreich ataxia rating scale (FARS) score and a favorable safety profile. Vatiquinone has been granted Orphan Drug Designa...

Yahoo | November 30, 2020

Here's What We Think About Therapeutics' (NASDAQ:PTCT) CEO Pay

This article will reflect on the compensation paid to Stuart Peltz who has served as CEO of PTC Therapeutics, Inc...

Yahoo | November 25, 2020

PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st at 11:45 a.m. ET.

Yahoo | November 19, 2020

The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbott Laboratories (NYSE: ABT ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Ascendis Pharma A/S (NASDAQ: ASND ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) Cardiff Oncology Inc (NASDAQ: CRDF ) Denali Therapeutics Inc (NASDAQ: DNLI ) - moved in sympathy with Biogen Inc (NASDAQ: BIIB ) Guardant Health Inc (NASDAQ: GH ) Halo...

Benzinga | November 5, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6937 seconds.